Abiliti 1 Day is the soft, single-use daily lens in Johnson & Johnson Vision’s Abiliti myopia-management family. Your child inserts a fresh, sterile lens each morning and discards it at night. It corrects distance vision like an ordinary contact lens, but its optical design is engineered to create a peripheral cue that discourages the eye from elongating — the underlying process that drives worsening myopia.
It is the daytime, soft-lens companion to Abiliti Overnight, the FDA-approved overnight orthokeratology lens we already fit at PersonalEyes. Together they reflect a growing, well-researched toolkit for protecting children’s vision.
Regulatory status: Abiliti 1 Day is not currently FDA-approved for myopia control in the United States. This page is educational, to help families understand an emerging option. Dr. Patel will recommend a proven, available treatment for your child today and revisit Abiliti 1 Day if and when it clears for U.S. use.
Why We’re Watching It
A fresh lens each day means no cleaning, no cases, and the lowest infection risk of any contact-lens modality — ideal for children.
Evaluated in multi-year studies abroad, including research in Australia, on slowing childhood myopia progression.
Corrects distance vision immediately — no overnight reshaping period like orthokeratology.
From Johnson & Johnson Vision, a long-established leader in soft contact-lens technology.
Complements Abiliti Overnight ortho-k — giving families day and overnight paths under one research-backed program.
Dr. Patel lectures on myopia control across Texas and tracks emerging options so your family hears about them early.
Book a myopia-control consultation with Dr. Patel to review every option — the proven treatments available today and the emerging ones on the horizon like Abiliti 1 Day.
Frequently Asked Questions
Abiliti 1 Day is a soft, single-use daily disposable contact lens developed by Johnson & Johnson Vision as part of its Abiliti myopia-management portfolio. Like other soft myopia-control lenses, it corrects a child’s distance vision while using a specialized optical design intended to slow the elongation of the eye that drives worsening nearsightedness. It sits alongside Abiliti Overnight (an FDA-approved orthokeratology lens we already offer) as the daytime, soft-lens member of the Abiliti family.
Not yet. Abiliti 1 Day has been studied and made available in several international markets, but as of now it is not FDA-approved for myopia control in the United States. We are watching its regulatory progress closely. In the meantime, Dr. Patel offers a full range of proven, FDA-cleared and clinically established options — MiSight 1 Day, orthokeratology, Stellest spectacle lenses, and low-dose atropine.
Abiliti 1 Day has been evaluated in multi-year international clinical studies, including research in Australia, examining its ability to slow myopia progression in children. Reported outcomes have been encouraging. Because the specific figures and study details continue to be published and reviewed, Dr. Patel will walk you through the current evidence and how it compares to the options available to your child today.
Myopia progresses fastest in childhood, and time lost is not recoverable — so the general guidance is to begin an effective, available treatment now rather than wait for a future option. Dr. Patel can start your child on a proven therapy today and, if Abiliti 1 Day becomes available and is the better fit later, transition care at that point.
Both are soft daily disposable lenses designed to slow myopia, but they come from different manufacturers and use different optical designs to create the peripheral signal that slows eye growth. MiSight (CooperVision) is currently the FDA-approved soft daily lens for myopia control in the U.S.; Abiliti 1 Day (Johnson & Johnson Vision) is an emerging option not yet approved here. Dr. Patel will explain the practical differences and recommend the best available fit for your child.